Microflora and Metabolomics of Crohn's Disease Patients
A Study Focused on the Microflora and Metabolomics of Crohn's Disease Patients
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200072
- Shanghai 10th People's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- individuals who were clear and signed the informed consent.
- Male and female.
Exclusion Criteria:
- Any one who can not provide accurate information.
- Any one who denies the study.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Active Crohn's disease group
Patients diagnosed with Crohn's disease after comprehensive evaluation of clinical symptoms, endoscopic features, radiological manifestations and histological features were recruited, and patients with CDAI score ≥ 150 were included in this group.
|
|
Crohn's disease remission group
Patients diagnosed with Crohn's disease after comprehensive evaluation of clinical symptoms, endoscopic features, radiological features and histological features were recruited, and patients with CDAI score < 150 were included in this group.
|
|
Healthy control group
Normal healthy people were randomly recruited as the control group
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Oral microbiota structure and function difference between active stage of Crohn's disease, remission of Crohn's disease and healthy controls
Time Frame: 3 months
|
The results were based on the 16S rRNA sequencing
|
3 months
|
|
Small intestinal microbiota structure and function difference between active stage of Crohn's disease, remission of Crohn's disease and healthy controls
Time Frame: 3 months
|
The results were based on the 16S rRNA sequencing
|
3 months
|
|
Sputum microbiota structure and function difference between active stage of Crohn's disease, remission of Crohn's disease and healthy controls
Time Frame: 3 months
|
The results were based on the 16S rRNA sequencing
|
3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Metabolic difference of blood samples between active stage of Crohn's disease, remission of Crohn's disease and healthy controls
Time Frame: 3 months
|
The metabolites of the blood samples by LC-MS will be detected
|
3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SHSYXK
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.